Lipid Or Oil Patents (Class 424/283.1)
  • Patent number: 9956195
    Abstract: A stable liposomal formulation for ocular delivery. The formulation contains a liposome that includes at least one lipid bilayer containing a phosphatidylcholine, and a prostaglandin F2? encapsulated in the liposome. Also provided is a method for treating an ocular disorder with the formulation.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: May 1, 2018
    Assignees: Nanyang Technological University, Singapore Health Services Pte Ltd
    Inventors: Subramanian Venkatraman, Jayaganesh V. Natarajan, Tina Howden, Freddy Boey
  • Patent number: 9592277
    Abstract: Antiviral compositions comprising a modified nuclease, or a plurality of such modified nucleases having at least one non-natural amino acid residue substituted for a naturally occurring amino acid in a parent nuclease are provided, as are methods of use and kits providing unit dosages of such compositions.
    Type: Grant
    Filed: April 14, 2005
    Date of Patent: March 14, 2017
    Assignee: Avirid, Inc.
    Inventors: Jacob G. Appelbaum, Rudolf I. Salganik
  • Patent number: 9580711
    Abstract: What is described is a lipid particle comprising the compound of formula I wherein R1 consists of alkyl, alkenyl, alkynyl, or cholesteryl; R2 consists of alkyl or alkenyl; L1 consists of alkyl, alkylene or alkenyl; X1 consists of —O—(CO)— or —(CO)—O—; X2 consists of S or O; L2 consists of a bond or alkylene; R3 consists of alkylene; and R4 and R5 are the same or different, each consisting of alkyl; or a pharmaceutical preparation thereof.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: February 28, 2017
    Assignee: Arcturus Therapeutics, Inc.
    Inventors: Joseph E. Payne, Padmanabh Chivukula, David Webb
  • Patent number: 9566326
    Abstract: An influenza vaccine adjuvanted with a sub-micron oil-in-water emulsion elicits significantly higher immune responses in human pediatric populations. Compared to an existing unadjuvanted pediatric influenza vaccine, the adjuvanted vaccines provided herein can induce in children a longer persistence of high serum antibody titers and also longer seroconversion and seroprotection. The improvement in immune responses is seen for both influenza A virus and influenza B virus strains, but it is particularly marked for influenza B virus. Moreover, while the existing vaccine provides poor immunity in children after a single dose, the adjuvanted vaccine provides high seroprotection rates against the influenza A virus H3N2 subtype even after a single dose. Furthermore, the adjuvanted vaccine offers significantly better seroprotection against mismatched strains of influenza A virus.
    Type: Grant
    Filed: June 21, 2013
    Date of Patent: February 14, 2017
    Assignee: Seqirus UK Limited
    Inventors: Audino Podda, Nicola Groth, Michele Pellegrini
  • Patent number: 9446117
    Abstract: The present invention provides Rotavirus antigenic polypeptides or antigens that elicit an immune response in animal or human against rotavirus, compositions comprising said rotavirus polypeptides, methods of vaccination against rotavirus, and kits for use with such methods and compositions. The invention further provide novel expression vectors for producing the vaccine antigenic polypeptides.
    Type: Grant
    Filed: February 14, 2013
    Date of Patent: September 20, 2016
    Assignee: Merial, Inc.
    Inventors: Russell F. Bey, Randy S Simonson, Kamesh Reddy Sirigireddy, Benjamin Matthew Hause
  • Patent number: 9439855
    Abstract: A pharmaceutical composition comprising an amphiphilic emulsifier, a polar liquid carrier and, optionally, a lipid component. The amphiphilic emulsifier form free-moving, optionally lipid-carrying, micelles (LMs) in the polar liquid carrier. The pharmaceutical composition is free of hemoglobin and fluorocarbon and can be used for treating conditions related to lack of blood supply and to raise the blood pressure and correct hypovolemia.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: September 13, 2016
    Assignee: Vivacelle Bio, Inc.
    Inventor: Cuthbert O. Simpkins
  • Patent number: 9365610
    Abstract: What is described is a compound of formula I wherein R1 consists of a linear or branched alkyl consisting of 1-18 carbons, an alkenyl or alkynyl consisting of 2 to 12 carbons, or a cholesteryl; R2 consists of a linear or branched alkyl or an alkenyl consisting of 1 to 18 carbons; L1 consists of a linear alkyl consisting of 5 to 9 carbons or, when R1 consists of a cholesteryl then L1 consists of a linear alkylene or alkenyl consisting of 3 to 4 carbons; X1 consists of —O—(CO)— or —(CO)—O—; X2 consists of S or O; L2 consists of a bond or a linear alkylene of 1 to 6 carbons; R3 consists of a linear or branched alkylene with 1 to 6 carbons; and R4 and R5 are the same or different, each consisting of a linear or branched alkyl of 1 to 6 carbons; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: June 14, 2016
    Assignee: Arcturus Therapeutics, Inc.
    Inventors: Joseph E. Payne, Padmanabh Chivukula, David Webb
  • Patent number: 9034337
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.
    Type: Grant
    Filed: February 23, 2007
    Date of Patent: May 19, 2015
    Assignee: Prothena Biosciences Limited
    Inventors: Dale B. Schenk, Eliezar Masliah, Manuel J. Buttini, Tamie J. Chilcote, Edward Rockenstein, Kate Dora Games
  • Patent number: 8999345
    Abstract: The disclosure provides adjuvants, immunogenic compositions, and methods useful for vaccination and immune response. In particular, the disclosure provides a class of adjuvants comprising cationic lipid:co-lipid mixtures and methods for delivering formulated compositions.
    Type: Grant
    Filed: August 3, 2012
    Date of Patent: April 7, 2015
    Assignee: Vical Incorporated
    Inventors: Jukka Hartikka, Sean M. Sullivan, Joel D. Enas, Alain Rolland
  • Publication number: 20150093410
    Abstract: The present invention provides compositions and methods for stimulating an immune response using cationic lipids alone or in combination with antigens.
    Type: Application
    Filed: November 3, 2014
    Publication date: April 2, 2015
    Inventors: Weihsu CHEN, Weili YAN, Kenya JOHNSON, Gregory CONN, Frank BEDU-ADDO, Leaf HUANG
  • Publication number: 20150086587
    Abstract: Oil-based adjuvant emulsions, immunogenic compositions, and methods of using the same to elicit immunological responses in a subject are provided. The oil-based adjuvants comprise a plant-derived surfactant, such as gum arabic, an aqueous component, and an oil. The adjuvant emulsions can be used to potentiate the immunological effects of active agents, including antigens derived from various pathogens and/or toxins. Immunogenic compositions comprising the adjuvant emulsions and various active agents are also provided, along with vaccine systems for therapeutic or prophylactic treatment of a subject using these adjuvants.
    Type: Application
    Filed: March 28, 2013
    Publication date: March 26, 2015
    Inventors: Jishu Shi, Loretta Pappan, Amy Beckley, Qixin Zhong
  • Publication number: 20150086592
    Abstract: This invention describes novel adjuvant compositions and formulations with excellent stability at refrigerated and room temperatures and up to and about 37° C. that can be produced at remarkably low costs. This invention describes novel vaccine compositions and formulations to treat and prevent urinary tract infections caused by gram-negative bacteria including Escherichia coli and multi-drug resistant E. coli. This invention also describes methods of administration of said novel vaccine compositions and formulations and methods of treatment to prevent and treat urinary tract infections caused by gram-negative bacteria including E. coli and multi-drug resistant E. coli.
    Type: Application
    Filed: September 23, 2014
    Publication date: March 26, 2015
    Inventors: Gary Eldridge, Steven M Martin
  • Patent number: 8969088
    Abstract: A substrate mimicking intercellular lipids in stratum corneum consisting of a substrate and a lipid membrane formed on the substrate, wherein the lipid membrane is formed from ceramide, palmitic acid and cholesterol, and the ceramide, palmitic acid and cholesterol are present at a mass ratio of 20-70%:10-60%:20-40% (ceramide:palmitic acid:cholesterol).
    Type: Grant
    Filed: September 1, 2009
    Date of Patent: March 3, 2015
    Assignee: Shiseido Company, Ltd.
    Inventors: Takuya Saiwaki, Takashi Oka, Yuichiro Mori, Toyoko Imae, Xiaojuan Wang, Masaki Ujihara
  • Publication number: 20150044279
    Abstract: Methods and compositions for enhancing the immune response to an IRM compound by depositing within a localized tissue region an IRM depot preparation that provides an extended residence time of active IRM within the localized tissue region.
    Type: Application
    Filed: October 6, 2014
    Publication date: February 12, 2015
    Inventors: Richard L. Miller, Mark A. Tomai, Ross M. Kedl, Isidro Angelo Eleazar Zarraga, Ronnie Ortiz, James D. Stoesz, Paul D. Wightman
  • Publication number: 20150030638
    Abstract: The present invention broadly relates to the use of certain ingenol derivatives as HIV reactivators of latent HIV virus in viral reservoirs. In another aspect, the present invention relates to an association comprising such ingenol derivatives and antiretroviral agents substantially active against actively replicating virus.
    Type: Application
    Filed: March 1, 2013
    Publication date: January 29, 2015
    Applicant: AMAZÔNIA FITOMEDICAMENTOS LTDA.
    Inventors: Luiz Francisco Pianowski, Amilcar Tanuri
  • Publication number: 20150024009
    Abstract: The invention provides an isolated genetically modified non-mammalian organism, wherein the activity of acyl-CoA:sterol acyltransferase/sterol O-acyltransferase (EC 2.3.1.26) and/or diacylglycerol acyltransferase/diacylglycerol O-acyltranferase (EC 2.3.1.20) and/or lecithin cholesterol acyl transferase/phospholipid: diacylglycerol acyltransferase (EC 2.3.1.158) and/or acyl CoA-wax alcohol acyltransferase (EC 2.3.1.75) is reduced or abolished in comparison with a corresponding wildtype organism, methods of use of such an organism, shuttle vehicles for making such an organism and methods for producing such an organism.
    Type: Application
    Filed: September 19, 2014
    Publication date: January 22, 2015
    Applicant: ORGANOBALANCE GMBH
    Inventors: Christine Lang, Andreas Raab
  • Publication number: 20150017191
    Abstract: Formulations and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed. The formulations generally comprise a TLR4 agonist and a metabolizable oil at a concentration of about 0.01%-1% v/v, wherein the hydrophobic:lipophilic balance (HLB) of the emulsion is greater than about 9.
    Type: Application
    Filed: February 7, 2013
    Publication date: January 15, 2015
    Inventors: Christopher Fox, Steven G. Reed, Susan Baldwin, Thomas Vedvick
  • Publication number: 20150017206
    Abstract: An improved method for the manufacture of an oil-in-water emulsion comprises using a microfluidisation device whose interaction chamber comprises a plurality of Z-type channels upstream of a back pressure chamber.
    Type: Application
    Filed: July 11, 2014
    Publication date: January 15, 2015
    Applicant: NOVARTIS AG
    Inventors: Harald RUECKL, Hanno SCHEFFCZIK, Barbara SANTRY
  • Patent number: 8906855
    Abstract: A pharmaceutical composition comprising an amphiphilic emulsifier, a polar liquid carrier and, optionally, a lipid component. The amphiphilic emulsifier form free-moving, optionally lipid-carrying, micelles (LMs) in the polar liquid carrier. The pharmaceutical composition is free of hemoglobin and fluorocarbon and can be used for treating conditions related to lack of blood supply and to raise the blood pressure and correct hypovolemia.
    Type: Grant
    Filed: August 9, 2013
    Date of Patent: December 9, 2014
    Assignee: Vivacelle Bio, Inc.
    Inventor: Cuthbert O. Simpkins
  • Patent number: 8906390
    Abstract: Compositions and methods for delivering cargo to cells are provided. One aspect provides a synthetic vesicle containing caveolin 1 or a fragment thereof in an amount effective to form lipid rafts in the vesicle. The synthetic vesicles can be used to deliver polynucleotides, proteins, therapeutic agents, or a combination thereof to specific membrane-bound compartments of a cell. In certain aspects, the synthetic vesicles can deliver cargo to cellular organelles such as mitochondria.
    Type: Grant
    Filed: March 26, 2007
    Date of Patent: December 9, 2014
    Assignee: Gencia Corporation
    Inventor: Shaharyar Khan
  • Patent number: 8894978
    Abstract: A new skin care system includes day and night skin cream compositions comprising nutrients and antioxidants for use by children between six months and eighteen years of age. The day skin cream composition provides protection from UV radiation and the night skin cream composition contains no sun protection ingredients and elevated levels of nutrients and antioxidants. A child-friendly bottle for each composition can be used by young children without difficulty. A fragrance included in each composition is popular with children, and the bottle for the day composition has graphics indicating day-time use and the bottle for the night composition has graphics indicating night-time use. The day composition is applied topically each day to the face after tooth-brushing, and the night composition is applied topically to the face each night after tooth-brushing.
    Type: Grant
    Filed: April 25, 2014
    Date of Patent: November 25, 2014
    Inventor: William Scott Prendergast
  • Publication number: 20140335049
    Abstract: Fraction A of Quil A can be used together with at least one other adjuvant for the preparation of an adjuvant composition, where the included adjuvant components act synergistically to enhance level of immune response and have synergistic immunomodulating activity on the co-administered antigens or immunogens. Other adjuvants can comprise saponins, naturally occurring, synthetic or semisynthetic saponin molecules; e.g. saponins and saponin fractions from Quil A, cell wall skeleton, block polymers, TDM, lipopeptides, LPS and LPS-derivatives, Lipid A from different bacterial species and derivatives thereof, e.g., monophosphoryl lipid A, CpG variants, CT and LT or fractions thereof.
    Type: Application
    Filed: July 29, 2014
    Publication date: November 13, 2014
    Inventors: Bror Morein, Karin Lövgren Bengtsson, Jill Ekström, Katarina Ranlund, Kefei Hu
  • Publication number: 20140314681
    Abstract: A hair regrowth system consisting of sensitization, growth, and maintenance kits for alopecia areata and related alopecia balding conditions. Graduated doses of specific engineered and or extracted haptens are included in a sensitization kit for initiating immune system response in hairless areas. A growth kit containing topical hormones to increase papilla size and vigor and a maintenance kit to sustain immune system response and papilla size and vigor for the long term are included in some embodiments.
    Type: Application
    Filed: February 26, 2014
    Publication date: October 23, 2014
    Inventor: George Davey
  • Patent number: 8846078
    Abstract: Brucellosis is a disease caused by facultative intracellular bacteria of the monospecific genus Brucella melitensis. The invention in one aspect is an immunogenic nucleic acid composition comprising DNA encoding Brucella melitensis Invasion Protein B, a polypeptide with at least 95% identity thereto, or an immunologically active fragment of either of these, and an adjuvant. In another aspect, the invention is a DNA vaccine composition comprising a plasmid vector having DNA encoding a polypeptide as recited above, in which said plasmid vector is adsorbed to a liposome. Other aspects of the invention include methods of inducing an enhanced immune response to Brucella infection in an animal, methods for the differential diagnosis in an animal of brucellosis and vaccination by an immunogenic nucleic acid composition having DNA encoding any of the above-recited polypeptides, and a kit for conducting said differential diagnosis methods.
    Type: Grant
    Filed: March 20, 2007
    Date of Patent: September 30, 2014
    Assignee: The Secretary of State for Environment, Food & Rural Affairs Acting through the Animal Health and Veterinary Laboratories Agency
    Inventors: Nicola Commander, Stephen Spencer
  • Patent number: 8828403
    Abstract: The present invention relates to the use of telomerase-derived peptides for the treatment of any cancer patients, particularly for the treatment of patients with renal or prostate cancer.
    Type: Grant
    Filed: June 16, 2009
    Date of Patent: September 9, 2014
    Assignee: Mediolanum Farmaceutici S.p.A.
    Inventors: Gilberto Filaci, Francesco Indiveri, Paolo Traverso
  • Publication number: 20140186406
    Abstract: The invention relates to compositions including a substance useful as an adjuvant for potentiating an immune response, and methods of using the composition in individuals with infections of tissue within or adjacent to a transformation zone, such as the transformation zone of the cervix or anal canal.
    Type: Application
    Filed: January 16, 2014
    Publication date: July 3, 2014
    Inventor: Jenny Colleen McCloskey
  • Publication number: 20140186378
    Abstract: This invention relates to immunogenic compounds which serve as ligands for NKT (natural killer T) cells and to methods of use thereof in modulating immune responses.
    Type: Application
    Filed: October 22, 2013
    Publication date: July 3, 2014
    Applicants: THE SCRIPPS RESEARCH INSTITUTE, THE ROCKEFELLER UNIVERSITY
    Inventors: Moriya TSUJI, David D. HO, Chi-Huey WONG, Douglass WU, Masakazu FUJIO, Xiangming LI
  • Patent number: 8758829
    Abstract: The present invention relates to a process for removing fluorine from krill material by subjecting the krill to disintegration and to an enzymatic hydrolysis process prior to or simultaneously with a removal of the exoskeleton particles producing a fluorine-reduced product. The process of the invention can process krill material with a high polar lipid content for producing superior quality, low fluorine, products suitable for the food and feed as well as the pharmaceutical, nutraceutical and cosmetic industry.
    Type: Grant
    Filed: September 14, 2009
    Date of Patent: June 24, 2014
    Assignee: Emerald Fisheries AS
    Inventors: Stig Tore Kragh Jansson, Jon Reidar Ervik, Leif Grimsmo
  • Patent number: 8758742
    Abstract: An encapsulation system is provided comprising nitrogen-purge, instant bonding encapsulation method. Specifically, the encapsulation system comprises a composition, a two-piece capsule comprising a capsule cap and a capsule body; a gas to purge oxygen from the composition within the capsule; and a sealing solution to seal the capsule cap to the capsule body. Associated methods for encapsulating compositions using the encapsulation system are also provided.
    Type: Grant
    Filed: April 11, 2007
    Date of Patent: June 24, 2014
    Assignee: Probiohealth, LLC
    Inventor: A. Satyanarayan Naidu
  • Publication number: 20140170174
    Abstract: When using squalene in a vaccine adjuvant, there is a possibility of contamination with polychlorinated biphenyls (PCBs). Environmental exposure to PCBs may adversely affect children's immune responses to routine vaccinations. Thus the invention uses squalene with low or no PCB contamination, particularly when derived from shark liver.
    Type: Application
    Filed: December 10, 2013
    Publication date: June 19, 2014
    Applicant: Novartis AG
    Inventor: Deborah L. Novicki
  • Publication number: 20140161887
    Abstract: Adjuvant compositions comprising type 1 interferon inducers, such as double-stranded RNA, in combination with antigen delivery systems and/or immunostimulatory molecules, such as immunostimulatory nucleic acid sequences, for enhancing the immune response of a coadministered antigen, are described.
    Type: Application
    Filed: November 15, 2013
    Publication date: June 12, 2014
    Applicant: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Derek O'Hagan, Nicholas Valiante
  • Patent number: 8747817
    Abstract: A new skin care system includes day and night skin cream compositions comprising nutrients and antioxidants for use by children between six months and eighteen years of age. The day skin cream composition provides protection from UV radiation and the night skin cream composition contains no sun protection ingredients and elevated levels of nutrients and antioxidants. A child-friendly bottle for each composition can be used by young children without difficulty. A fragrance included in each composition is popular with children, and the bottle for the day composition has graphics indicating day-time use and the bottle for the night composition has graphics indicating night-time use. The day composition is applied topically each day to the face after tooth-brushing, and the night composition is applied topically to the face each night after tooth-brushing.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: June 10, 2014
    Inventor: William Scott Prendergast
  • Patent number: 8728465
    Abstract: Compositions comprising dendritic cells pulsed with tumor lysate and at least one toll-like receptor (TLR) ligand which may be used for eliciting a specific immune response in a mammal in need thereof for treating diseases including a tumor are disclosed. Also disclose are methods of activating dendritic cells, comprising providing at least one toll-like receptor (TLR) ligand; and pulsing a dendentic cell with the at least one TLR ligand. A method further comprises pulsing the dendritic cell with a tumor lysate.
    Type: Grant
    Filed: June 17, 2009
    Date of Patent: May 20, 2014
    Assignee: Cedars-Sinai Medical Center
    Inventors: Keith L. Black, Dwain Morris-Irvin, Moshe Arditi
  • Publication number: 20140134210
    Abstract: The present invention relates to: a pharmaceutical composition containing lysophosphatidylcholine or analogs thereof and antibiotics as active ingredients for boosting immunity or the treatment of bacterial infections; a method for boosting immunity or the treatment of bacterial infections, which comprises a step for administering the composition; and a kit containing the composition for boosting immunity or the treatment of bacterial infections.
    Type: Application
    Filed: June 22, 2012
    Publication date: May 15, 2014
    Applicant: ARIMED INC.
    Inventors: Jai Jun Chuong, Sae Kwang Ku, Dong Keun Song
  • Publication number: 20140112979
    Abstract: The invention discloses a method for the formation of liposomes by using high shear mixing of aqueous solution of lipid powder; the lipid powder can be produced by any known technique. Components of the liposomes include but are not limited to cationic lipids, immunostimulatory/immunopotentiators and macromolecules as components for the liposome formation. The disclosed method describes the formulation of stable liposomes solitary or complexing high concentrations of macromolecules such as proteins, DNA and RNA having opposite charge of the liposomes by high shear mixing where aggregation is avoided due to the formulation method.
    Type: Application
    Filed: July 3, 2012
    Publication date: April 24, 2014
    Applicant: Statens Serum Institut
    Inventors: Lars Vibe Andreasen, Grith Wood, Dennis Christensen
  • Patent number: 8703154
    Abstract: A vaccine adjuvant which, based on the 100% mass thereof, includes between 10% and 95% of a mineral oil containing: between 0.05 mass-% and 10 mass-% hydrocarbon chains having less than 16 carbon atoms, and between 0.05 mass-% and 5 mass-% hydrocarbon chains having more than 28 carbon atoms. In addition, the adjuvant has a P/N ratio, corresponding to the ratio of the mass quantity of the paraffinic hydrocarbon chains to the mass quantity of the naphthenic hydrocarbon chains, of between 2.5 and 3, the adjuvant being intended for the production of a vaccine composition to prevent coccidiosis.
    Type: Grant
    Filed: January 14, 2011
    Date of Patent: April 22, 2014
    Assignee: Societe d'Exploitation de Produits pour les Industries Chimiques SEPPIC
    Inventors: Laurent Dupuis, Francois Bertrand, Sebastien Deville
  • Patent number: 8703095
    Abstract: The invention relates to an oil-in-water adjuvant emulsion which comprises at least: squalene, an aqueous solvent, a polyoxyethylene alkyl ether nonionic surfactant, a hydrophobic nonionic surfactant, which emulsion is thermoreversible, and wherein 90% of the population by volume of the oil drops has a size less than 200 nm. The invention also relates to a process for preparing an immunogenic composition according to which at least one vaccine antigen is mixed with an oil-in-water emulsion, wherein the oil-in-water emulsion is obtained by means of a temperature-variation phase-inversion process.
    Type: Grant
    Filed: July 7, 2006
    Date of Patent: April 22, 2014
    Assignee: Sanofi Pasteur S.A.
    Inventors: Marie-Francoise Klucker, Francois Dalencon, Patricia Probeck-Quellec
  • Patent number: 8697138
    Abstract: This invention discloses methods of using krill oil and compositions comprising krill oil to treat risk factors for metabolic, cardiovascular, and inflammatory disorders. The present invention also relates to methods of using compositions comprising krill oil to modulate biological processes selected from the group consisting of glucose metabolism, lipid biosynthesis, fatty acid metabolism, cholesterol biosynthesis, and the mitochondrial respiratory chain. The present invention further includes pharmaceutical and/or nutraceutical formulations made from krill oil, methods of making such formulations, and methods of administering them to treat risk factors for metabolic, cardiovascular, and inflammatory disorders.
    Type: Grant
    Filed: May 28, 2010
    Date of Patent: April 15, 2014
    Assignee: Aker Biomarine AS
    Inventors: Inge Bruheim, Snorre Tilseth, Jeffery Cohn, Mikko Griinari, Daniele Mancinelli, Nils Hoem, Hogne Vik, Sebastiano Banni
  • Patent number: 8678184
    Abstract: An improved method for the manufacture of an oil-in-water emulsion involves three procedures: (i) preparation of a preliminary emulsion; (ii) microfluidization of the preliminary emulsion to reduce its droplet size; and (iii) filtration of the microfluidized emulsion through a hydrophilic membrane. The emulsions are useful as vaccine adjuvants.
    Type: Grant
    Filed: December 3, 2010
    Date of Patent: March 25, 2014
    Assignee: Novartis AG
    Inventors: Gottfried Kraus, Robert Eskes
  • Publication number: 20140017279
    Abstract: High loading of lipophilic pharmacological agents (in particular, lipophilic immunopotentiators) in oil-in-water emulsions can result in crystallisation of the lipophilic agent. To overcome this problem the invention uses an oil-in-water emulsion in combination with a crystallisation inhibitor, and this combination provides emulsions which can be loaded with high levels of lipophilic pharmacological agents.
    Type: Application
    Filed: January 27, 2012
    Publication date: January 16, 2014
    Applicant: Novartis AG
    Inventors: Luis Brito, Cary Singh, Derek O'hagan
  • Publication number: 20140017285
    Abstract: To formulate amphiphilic pharmacological agents (in particular, amphiphilic immunopotentiators) in oil-in-water emulsions the invention provides an oil-in-water emulsion comprising an aqueous phase, an oil phase, a surfactant, and a phospholipid.
    Type: Application
    Filed: March 23, 2012
    Publication date: January 16, 2014
    Applicant: NOVARTIS AG
    Inventors: Luis Brito, Manmohan Singh, Derek O'Hagan
  • Patent number: 8628784
    Abstract: An adjuvant composition comprising monophosphoryl lipid A or a derivative of monophposphoryl lipid A adsorbed onto an aluminium salt particle.
    Type: Grant
    Filed: February 28, 2008
    Date of Patent: January 14, 2014
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventor: Nathalie Garcon
  • Patent number: 8628786
    Abstract: When using squalene in a vaccine adjuvant, there is a possibility of contamination with polychlorinated biphenyls (PCBs). Environmental exposure to PCBs may adversely affect children's immune responses to routine vaccinations. Thus the invention uses squalene with low or no PCB contamination, particularly when derived from shark liver.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: January 14, 2014
    Assignee: Novartis AG
    Inventor: Deborah L. Novicki
  • Patent number: 8618056
    Abstract: A pharmaceutical composition comprising a lipid component; an amphiphilic emulsifier; and a polar liquid carrier. The lipid component and the amphiphilic emulsifier form free-moving lipid-carrying micelles (LMs) in the polar liquid carrier. The pharmaceutical composition is free of hemoglobin and fluorocarbon and can be used for treating conditions related to lack of blood supply and to raise the blood pressure.
    Type: Grant
    Filed: October 14, 2011
    Date of Patent: December 31, 2013
    Inventor: Cuthbert O. Simpkins
  • Publication number: 20130337044
    Abstract: The invention relates to a pharmaceutical composition for the modulation of effector T cell responses made of one or more preparations and comprising a therapeutically effective dose of at least one recombinant human C3-derivative and of at least one antigen or allergen.
    Type: Application
    Filed: June 14, 2013
    Publication date: December 19, 2013
    Inventors: Reinhard Bredehorst, Thomas Grunwald, Markus Ollert, Carsten Schmidt-Weber, Edzard Spillner
  • Patent number: 8603488
    Abstract: The invention provides methods of cultivating microalgae photoautotrophically outdoors to prepare concentrated microalgae products containing eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) docosahexaenoic acid, two long-chain polyunsaturated fatty acids found in fish oil that are very important for human and animal health. It also provides concentrated microalgae products containing EPA and DHA and purified lipid products containing EPA and DHA purified from microalgae.
    Type: Grant
    Filed: September 25, 2011
    Date of Patent: December 10, 2013
    Assignee: Parry Nutraceuticals, Division of E.I.D. Parry (India) Ltd
    Inventors: Swati Sebastian Thomas, Swaminathan Kumaravel
  • Publication number: 20130309273
    Abstract: The disclosure provides compositions relating to thermostable vaccines and methods of preparing same. Specifically, the disclosure provides for methods of preparing thermostable vaccines based on a recombinant ricin neurotoxin protein and uses of co-adjuvants to develop a composition capable of eliciting an immune response in a subject.
    Type: Application
    Filed: May 17, 2012
    Publication date: November 21, 2013
    Inventors: Kimberly Hassett, Pradyot Nandi, Robert Brey, John Carpenter, Theodore W. Randolph
  • Patent number: 8580280
    Abstract: This invention relates to adjuvant formulations comprising various combinations of triterpenoids, sterols, immunomodulators, polymers, and Th2 stimulators; methods for making the adjuvant compositions; and the use of the adjuvant formulations in immunogenic and vaccine compositions with different antigens. This invention further relates to the use of the formulations in the treatment of animals.
    Type: Grant
    Filed: June 24, 2009
    Date of Patent: November 12, 2013
    Assignee: Zoetis LLC
    Inventors: Paul J. Dominowski, Ramasamy M. Mannan, Richard L. Krebs, James R. Thompson, Tedd A. Childers, Mary K. Olsen, Robert J. Yancey, Jr., Risini Weeratna, Shucheng Zhang, Cedo M. Bagi
  • Publication number: 20130295129
    Abstract: Lipid conjugates for enhanced delivery of cargo to the lymph nodes are disclosed. The lipid conjugates typically include three domains: a lipophilic domain that binds to albumin, a polar block domain, and a cargo such as a molecular adjuvant or immunostimulatory compound (such as an oligonucleotide) or antigenic peptide. Depending on the cargo, the length and compositions of the polar block can be tailored to push the equilibrium toward albumin binding, stable micelle formation, or cell insertion. The conjugates can be administered to a subject, for example, a subject with cancer or an infection, to induce or enhance a robust immune response in the subject.
    Type: Application
    Filed: March 15, 2013
    Publication date: November 7, 2013
    Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventor: Massachusetts Institute of Technology
  • Publication number: 20130273144
    Abstract: Provided in some embodiments are compositions comprising a compound having a structure according to Formula A or Formula B: or a pharmaceutically acceptable salt, tautomer or hydrate thereof, where X2 is a bond or linker, X3 is bond or —PO4—, and X1, R1, R2, R3, and n are described herein. Also provided in some embodiments are methods for making and using such compounds and compositions.
    Type: Application
    Filed: February 25, 2013
    Publication date: October 17, 2013
    Inventors: Roberto Maj, Franco Pattarino, Emanuela Mura, Alcide Barberis